A MULTICENTER NON-INFERIORITY STUDY OF EFFICACY AND SAFETY OF GENERIC IMATINIB IN CHRONIC MYELOID LEUKEMIA ¿ FINAL ANALYSIS KBB Pagnano; ECM Miranda; I Bendit; F Seguro; M Conchon; NN Gonçalves; GH Magalhães; N Clementino; D Borducchi; N Andari; A Coelho; I Luise; L Fogliatto; J Bortolini; R Centrone; C Boquimpani; CA Souza;

AVALIAÇÃO DA COVID-19 EM PACIENTES COM LEUCEMIA MIELOIDE CRÔNICA LVDN Fechio; J Bortolini; AC Toreli; H Machado; R Zulli; GO Duarte; S Medina; F Pericole; CA Souza; KBB Pagnano;

IMMUNE MATURATION AND CHECKPOINT DYNAMICS DURING TYROSINE KINASE INHIBITOR DOSE REDUCTION PREDICT RELAPSE RISK IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDERGOING TREATMENT DISCONTINUATION LS Binelli; LC Palma; CAB Garcia; M Medeiros; AG de Carvalho; BL Adjafre; LO Marani; PS Scheucher; JLS Schiavinato; PMM Garibaldi; RL Pacca; FS Seguro; RS Tavares; LL Almeida; RS Welner; KBB Pagnano; LL de Figueiredo-Pontes;